Mike Cornejo

Mike Cornejo

Auto-generated profile, based on publicly available information

Mike Cornejo

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BEBenelita T. Elie
Benelita T. Elie
JFJacob Fernández-Gallardo
Jacob Fernández-Gallardo
NCNatalia Curado
Natalia Curado
MCMike A. Cornejo
Mike A. Cornejo
JRJoe W. Ramos
Joe W. Ramos
Maria ContelMaria Contel
Maria Contel

15 April 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
Patricia PereiraPatricia Pereira
Patricia Pereira
KEKimberly J. Edwards
Kimberly J. Edwards
KMKomal Mandleywala
Komal Mandleywala
LCLukas M Carter
Lukas M Carter
FEFreddy Escorcia
Freddy Escorcia
JLJason S. Lewis
Jason S. Lewis
Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to radiotherapy, chemotherapy, or a combination of these modalities, and surgery remains the only curative intervention for localized disease. Although cancer-associated fibroblasts (CAF) are abundant in PDAC tumors, the effects of radiotherapy on CAFs and the response of PDAC cells to radiotherapy are unknown. Using patient samples and orthotopic PDAC biological models, we showed that radiotherapy increased inducible nitric oxide synthase (iNOS) in the tumor tissues. Mechanistic in vitro studies showed that, although undetectable in radiotherapy-activated tumor cells, iNOS expression and nitric oxide (NO) secretion were significantly increased in CAFs secretome following radiotherapy. Culture of PDAC cells with conditioned media from radiotherapy-activated CAFs increased iNOS/NO signaling in tumor cells through NF-κB, which, in turn, elevated the release of inflammatory cytokines by the tumor cells. Increased NO after radiotherapy in PDAC contributed to an acidic microenvironment that was detectable using the radiolabeled pH (low) insertion peptide (pHLIP). In murine orthotopic PDAC models, pancreatic tumor growth was delayed when iNOS inhibition was combined with radiotherapy. These data show the important role that iNOS/NO signaling plays in the effectiveness of radiotherapy to treat PDAC tumors.Significance: A radiolabeled pH-targeted peptide can be used as a PET imaging tool to assess therapy response within PDAC and blocking iNOS/NO signaling may improve radiotherapy outcomes.

28 March 2019 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
NCNatalia Curado
Natalia Curado
NGNora Giménez
Nora Giménez
KMKirill Miachin
Kirill Miachin
MAMélanie Aliaga‐Lavrijsen
Mélanie Aliaga‐Lavrijsen
MCMike A. Cornejo
Mike A. Cornejo
Maria ContelMaria Contel
Maria Contel

30 January 2019 in ACS Nano
Verified
Journal Article
Closed access
JSJiye Son
Jiye Son
DKDaniela Kalafatovic
Daniela Kalafatovic
MKMohit Kumar
Mohit Kumar
BYBarney Yoo
Barney Yoo
MCMike A. Cornejo
Mike A. Cornejo
RURein V. Ulijn
Rein V. Ulijn

25 February 2020 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
Jeroen A.C.M. GoosJeroen A.C.M. Goos
Jeroen A.C.M. Goos
MDMaria Davydova
Maria Davydova
TDThomas R. Dilling
Thomas R. Dilling
ACAndrew Cho
Andrew Cho
MCMike A. Cornejo
Mike A. Cornejo
JLJason S. Lewis
Jason S. Lewis

27 January 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
EPEdwin C. Pratt
Edwin C. Pratt
DBDavid Bauer
David Bauer
LCLukas M Carter
Lukas M Carter
MCMike Cornejo
Mike Cornejo
SCSebastian E. Carrasco
Sebastian E. Carrasco
JLJason S. Lewis
Jason S. Lewis
Purpose: Trophoblast cell surface antigen-2 (Trop-2) is a membrane-bound antigen associated with cancer invasiveness and poorer patient outcomes. Delivery of therapeutics via Trop-2 targeting antibody–drug conjugates (ADC) has proven to be a viable and FDA-approved model. However, in the clinic, ADC dosing is not based on Trop-2 positivity or expression, leading to potential adverse effects if the antigen membrane level on cancer cells is insufficient for targeting. The challenge of adequate patient and therapy selection can be overcome by leveraging the theranostic approach. We previously established a Trop-2.2 antibody for immunoPET imaging, allowing us to theoretically select patients with positive Trop-2 lesions. Experimental Design: In this work, the antibody Trop-2.2 was repurposed for lutetium-177, actinium-225, and lead-212 radiotherapies. We explored the benefits of direct, tandem, pretargeted, and fractionated approaches to radiopharmaceutical dosing. Results: Therapy with the α emitter 225Ac regressed tumors, with eight out of 10 mice alive after 150 days. Alternatively, 212Pb, a shorter-lived in vivo α generator therapeutic, was found to be more effective when harnessing the pretargeting (PreT) strategy compared with a directly labeled approach. Our in-house 212Pb production allowed us to investigate fractionated dosing on a weekly basis. Fractionation resulted in tumor reductions through 12 weeks of therapy with minimal and reversible blood toxicity for the lowest dose. With repeat administrations, we found pathologically significant renal and ovarian toxicity attributable to 212Pb administration but an otherwise effective PreT method. Conclusions: In this study, we provide several direct and pretargeted radiopharmaceutical variants yielding therapeutic benefit for a Trop-2.2–expressing pancreatic cancer model.